A propitious time for initiating clinical trials in Patients with heart failure with reduced ejection fraction and an estimated glomerular filtration ate <30 mL/min with an mineralocorticoid receptor antagonist and a K1 binder: 'The forbidden fruit'

European Heart Journal

Volumn 37, Issue 41, 2016, Pages 3130-3134

  Epstein, Murray ^a   Pitt, Bertram C ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINERALOCORTICOID ANTAGONIST;

ARTICLE; CHRONIC KIDNEY FAILURE; ESTIMATED GLOMERULAR FILTRATION RATE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; LABORATORY TEST; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); COMPLICATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGIC MONITORING; PHYSIOLOGY;

GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MONITORING, PHYSIOLOGIC; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; STROKE VOLUME;

EID: 85015907626     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw222     Document Type: Article

References (30)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
2. Epstein M. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. Lancet Diabetes Endocrinol 2015;3:993-1003.
3. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-495.
4. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003;87: S24-S31.
5. Virani SA, Khosla A, Levin A. Chronic kidney disease, heart failure and anemia. Can. J. Cardiol 2008;24(Suppl. B):22B-24B.
6. Shiba N, Shimokawa H. Chronic kidney disease and heart failure-bidirectional close link and common therapeutic goal. J. Cardiol 2011;57:8-17.
7. McMurray JJV. Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. Kidney Int 2005;68:1419-1426.
8. van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L, Maggioni AP, Voors AA. Co-morbidities in patients with heart failure: An analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014;16:103-111.
9. Chronic kidney disease identified in the claims data. 2009 Annual Data Report, United States Renal Data System. http://www.usrds.org/.
10. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin aldosterone system inhibitors. Am J Manag Care 2015;21(11 Suppl.):S212-S220.
11. Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, Chiswell K, Patel UD. The landscape of clinical trials in nephrology: A systematic review of Clinicaltrials. gov. Am J Kidney Dis 2014;63:771-780.
12. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. J Am Med Assoc 2006;296:1377-1384.
13. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006;70:2021-2030.
14. Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, Coca SG. Representation of patients with kidney disease in trials of cardiovascular interventions: An updated systematic review. JAMA Intern Med 2016;176:121-124.
15. Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. Heart 2013;99:365-372.
16. Ishida JH, Johansen KL. Exclusion of patients with kidney disease from cardiovascular trials. JAMA Intern Med 2016;176:124-125.
17. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure. J Am Coll Cardiol 2012;60:2082-2089.
18. Eschalier R, McMurray JJV, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function analyses of the EMPHASIS-HF Study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). J Am Coll Cardiol 2013;62:1585-1593.
19. Edner M, Benson L, Dahlström U, Lund LH. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: A prospective propensity score-matched cohort study. Eur Heart J 2015;36:2318-2326.
20. Bakris GL, Pitt B,Weir MR, FreemanMW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The AMETHYST-DN randomized clinical trial. J Am Med Assoc 2015;314:151-161.
21. Epstein M, Mayo M, Garza D, Stasiv Y, Zawadski R, Berman L, Wilson D, Bakris G. Patiromer controls hyperkalemia in resistant hypertensive patients on RAASi, with diabetic kidney disease. Circulation 2015;132(Suppl. 3):Abstract 14271.
22. Wright S, Klausner D, Baird B, Williams ME, Steinman T, Tang H, Ragasa R, Goldfarb-Rumyantzev AS. Timing of dialysis initiation and survival in ESRD. Clin J Am Soc Nephrol 2010;5:1828-1835.
23. U.S. Renal Data System: USRDS 2005 Annual Data Report. Bethesda, MD: National Institutes of Health; 2005.
24. Tattersall J, Greenwood R, Farrington K. Urea kinetics and when to commence dialysis. Am J Nephrol 1995;15:283-289.
25. Hsu T-W, Liu J-S, Hung S-C et al. Renoprotective effect of renin-angiotensinaldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med 2014;174:347-354.
26. Ruggenenti P, Perna A, Remuzzi G, Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: A post hoc analysis of the REIN trial results: Ramipril efficacy in nephropathy. J Am Soc Nephrol 2001;12:2832-2837.
27. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006;354:131-140.
28. Yancy CW, Jessup M, Bozkurt B et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-e239.
29. Cooper LB, Hammill BG, Peterson ED. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. J Am Med Assoc 2015;314:1973-1975.
30. Rossignol P, Dobre D, McMurray JJ, Swedberg K et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014;7:51-58.